Mixed data from a phase II trial in October 2014 may have presaged Eleven Biotherapeutics Inc.'s phase III top-line failure in severe allergic conjunctivitis (pink eye) with the interleukin-1 signaling inhibitor EBI-005 (isunakinra), which also proved a dud in the late-stage experiment for dry eye disease in May 2015.